tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

EBR Systems Announces Australian Investor Roadshow to Showcase Wireless Cardiac Pacing Technology

Story Highlights
  • EBR Systems specializes in wireless cardiac pacing technology for heart failure.
  • EBR Systems is hosting an investor roadshow in Australia to discuss technology and commercialization.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
EBR Systems Announces Australian Investor Roadshow to Showcase Wireless Cardiac Pacing Technology

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

EBR Systems, Inc. Shs Chess Depository Interests Repr 1 Sh ( (AU:EBR) ) has issued an announcement.

EBR Systems, Inc. has announced an investor roadshow in Australia from November 4 to November 6, 2025, offering securityholders a chance to engage with the company’s Chief Corporate Development Officer, Andrew Shute, and an Australian-based implanter. The roadshow will provide updates on recent milestones and insights into the commercialization pathway of EBR’s innovative wireless cardiac pacing technology. This initiative reflects EBR’s commitment to enhancing stakeholder engagement and expanding its market presence, potentially impacting its industry positioning by showcasing its cutting-edge technology and future applications.

The most recent analyst rating on (AU:EBR) stock is a Buy with a A$2.48 price target. To see the full list of analyst forecasts on EBR Systems, Inc. Shs Chess Depository Interests Repr 1 Sh stock, see the AU:EBR Stock Forecast page.

More about EBR Systems, Inc. Shs Chess Depository Interests Repr 1 Sh

Silicon Valley-based EBR Systems, Inc. is a pioneering company in the cardiac rhythm disease management industry, specializing in wireless cardiac pacing technology. Their proprietary Wireless Stimulation Endocardially (WiSE) technology aims to improve the physiological effectiveness of cardiac stimulation by eliminating the need for traditional pacing leads, which are often associated with complications. EBR’s initial product targets heart failure patients requiring Cardiac Resynchronisation Therapy (CRT) and is currently available in the US, with future plans to expand its applications.

Average Trading Volume: 669,086

Technical Sentiment Signal: Hold

Find detailed analytics on EBR stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1